HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Immunotherapy ‘revolutionary’ for lung cancer, but questions remain about cost, biomarkers
-
- Back to the future: Chemotherapy dosing in overweight and obese patients with cancer Gary H. Lyman, MD MPH
- When worlds collide: Chemotherapy near the end of life Arif Kamal, MD, MHS, FACP, FAAHPM, FASCO
- Interim DeCOG results provide reassurance for patients who delay CLND after positive sentinel node Vernon K. Sondak, MD
- Research reveals fine line between ‘one more try’ and ‘a bridge too far’ John Sweetenham, MD, FRCP, FACP
- FDA approves Odomzo for locally advanced basal cell carcinoma
- FDA expands approval of Kyprolis for relapsed multiple myeloma
- FDA grants breakthrough drug designation to Lenvima for advanced RCC
- FDA grants breakthrough therapy designation to Azedra for pheochromocytoma, paraganglioma
-
- FDA grants orphan drug designation to Ad-RTS-hIL-12 for malignant glioma
- FDA grants orphan drug designation to Anisina for neuroblastoma
- Bladder cancer risk not increased with pioglitazone therapy
- BMI should not influence chemotherapy dose reductions for ovarian cancer
- Breast, ovarian cancer risks vary by BRCA mutation location, type
- Certain biomarkers predict anthracycline chemotherapy benefit in breast cancer
- Comorbidities increase risk for lung cancer mortality
- Conditional survival estimates valuable for intrahepatic cholangiocarcinoma
-
- Early initiation of palliative care offers benefits to patients, family caregivers
- Fever present in HHV-6 reactivation after pediatric stem cell transplant
- Gene assay predicts recurrence following nephrectomy in renal cell carcinoma
- Indoor tanning rates decline among US adults
- Mastectomy with immediate reconstruction doubles risk for SSI
- One-third of women with breast cancer desire genetic testing
- Palliation should be comparable for patients with hematologic malignancies, solid tumors
- Palliative chemotherapy fails to improve quality of life near death
-
- Pegylated interferon alfa-2b provides minimal benefit as maintenance therapy for osteosarcoma
- Radioactive iodine for thyroid cancer may not increase breast cancer risk
- Researchers find HBV screening rate low in patients undergoing chemo
- Researchers identify factors that increase mortality risk among patients with MPNs
- Routine CT does not improve occult cancer detection after unprovoked VTE
- Statin use before ADT delays prostate cancer progression
- Support, survivorship concerns unmet in thyroid cancer
- Surveillance imaging offers little benefit for DLBCL in first remission
-
- Systemic therapy underutilized in NSCLC treatment, particularly among older patients
- Treatment of stage I breast cancer has intensified over time
- Vena cava filter as anticoagulation add-on did not reduce symptomatic recurrent pulmonary embolism
- Vitamin D levels may affect follicular lymphoma outcomes
- ASTRO elects three new board members
- Center for Childhood Cancer and Blood Disorders appoints director
- MD Anderson Cancer Center named best cancer hospital in nation
- Change in radiation dose distribution may reduce late rectal bleeding
-
- Exome sequencing found to assist in determining HCC therapy
- Radiation exposure from mammography screening may have been overestimated